Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02320812 · ClinicalTrials.gov registry record · Phase 1
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa
A Phase 1 study, sponsored by jCyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02320812 is a Phase 1 study that has completed, run by jCyte. The registered enrollment target is 28 participants.
The verdict
NCT02320812, a Phase 1 study, has completed, sponsored by jCyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study evaluates the safety and potential activity of a single dose of live human retinal progenitor cells (jCell) administered to adults with retinitis pigmentosa. Four different dose levels of cells will be assessed in each of two groups of patients.
Interventions
- BIOLOGICAL human retinal progenitor cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-07-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02320812
The ClinicalTrials.gov registry entry for NCT02320812 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is jCyte, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which human retinal progenitor cells is the first listed.
NCT02320812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02320812 about?
NCT02320812 is a clinical study titled "Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa". This study evaluates the safety and potential activity of a single dose of live human retinal progenitor cells (jCell) administered to adults with retinitis pigmentosa. Four different dose levels of cells will be assessed in each of two groups of patients.
What is the current status of trial NCT02320812?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2015-06. Estimated completion is 2017-07-19.
What interventions are being tested in trial NCT02320812?
The interventions under investigation include: human retinal progenitor cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02320812?
This trial is sponsored by jCyte, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.